MRK - CIK 0000310158
The table below shows Merck & Co., Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | $16.47B | $21.47B | $13.01B | $19.09B | - | $10.25B |
| Capital expenditure | $4.11B | $3.37B | $3.86B | $4.39B | $4.45B | - |
| Investing cash flow | -$13.74B | -$7.73B | -$14.08B | -$4.96B | - | -$9.44B |
| Dividends paid | $8.18B | $7.84B | $7.45B | $7.01B | $6.61B | $6.21B |
Merck & Co., Inc. reported operating cash flow of $16.47B for fiscal year 2025. That is down 23.3% from $21.47B in fiscal 2024. Over the 10 fiscal years shown, operating cash flow grew from $12.54B (FY 2015) to $16.47B. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| Stock buybacks | $5.08B | $1.31B | $1.35B | $0.00 | $840.00M | $1.28B |
| Financing cash flow | -$1.92B | -$7.03B | -$4.81B | -$9.12B | - | -$2.83B |